Evaluating Virtual Reality to Improve Quality of Life for Cancer Patients During Chemotherapy

What this Trial Is About

Researchers are evaluating the impact of virtual reality on managing anxiety, nausea, and vomiting in cancer patients receiving their first line of chemotherapy. This clinical study aims to improve quality of life and assess patient and nursing staff satisfaction during chemotherapy treatment. The study is interventional, randomized, and controlled, involving two groups to compare virtual reality with standard care. Participants are divided into two groups one group experiences a 20-minute virtual reality session during each of the first three chemotherapy cycles, while the other group receives conventional care without virtual reality. These sessions occur during chemotherapy, each lasting more than 30 minutes. The study includes a pre-inclusion visit one week before the first cycle and follow-up visits at 3, 6, and 9 months after completing the three chemotherapy cycles. During the study, participants will complete questionnaires and assessments measuring quality of life, anxiety, pain, fatigue, nausea, and vomiting using tools like the QLQ-C30 questionnaire, Visual Analogue Scale VAS, and MASCC Antiemesis Tool MAT. Patient and nurse satisfaction will be evaluated after chemotherapy sessions. Vital signs such as heart rate and blood pressure will be monitored. The total study duration includes chemotherapy cycles plus follow-up visits extending up to nine months post-treatment.

Impact of Virtual Reality on the Quality of Life of Oncology Patients